ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer
M. A. Voronkova, B. Johnson, N. Gandhi, J. M. Koomen, M Patrick, S. Shanthi Bhupathi, V. M. Wu, A. Elliott, A. Vanderwalde, B. Halmos, L. A. Hazlehurst · 2024
Read ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer by M. A. Voronkova, B. Johnson, N. Gandhi, J. M. Koomen, M Patrick, S. Shanthi Bhupathi, V. M. Wu, A. Elliott, A. Vanderwalde, B. Halmos, L. A. Hazlehurst (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11535241.txt.
Description
Voronkova and co-authors identify a protein that flags poor outlook in a genetic subtype of lung cancer, in this 2024 paper. The protein, ERO1A, helps fold other proteins in the cell's export workshop. The cancer subtype carries mutations in the EGFR growth receptor.
In patient samples, tumors high in this protein also made more of the machinery that secretes proteins, plus more matrix material and matrix-editing enzymes. Deleting the protein from cancer cell lines cut colony growth, sphere formation, and tumor growth in animals, and changed response to the targeted drug osimertinib. Knockout cells also secreted less of two matrix-linked proteins. The authors argue the protein reshapes the tumor's surroundings to favor spread, making it both a warning sign and a possible drug target in this cancer subtype.
Catalog record
| CREATOR | M. A. Voronkova, B. Johnson, N. Gandhi, J. M. Koomen, M Patrick, S. Shanthi Bhupathi, V. M. Wu, A. Elliott, A. Vanderwalde, B. Halmos, L. A. Hazlehurst |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |